Samsara BioCapital LLC Takes $36.45 Million Position in Upstream Bio, Inc. (NASDAQ:UPB)

Samsara BioCapital LLC acquired a new stake in shares of Upstream Bio, Inc. (NASDAQ:UPB) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 2,217,146 shares of the company’s stock, valued at approximately $36,450,000. Upstream Bio accounts for approximately 4.9% of Samsara BioCapital LLC’s holdings, making the stock its 6th biggest holding.

Other large investors also recently bought and sold shares of the company. US Bancorp DE purchased a new position in Upstream Bio during the 4th quarter worth $27,000. Legal & General Group Plc purchased a new stake in shares of Upstream Bio during the fourth quarter worth about $28,000. Summit Investment Advisors Inc. acquired a new position in shares of Upstream Bio during the fourth quarter valued at about $30,000. Tower Research Capital LLC TRC purchased a new position in shares of Upstream Bio in the 4th quarter valued at approximately $47,000. Finally, Corebridge Financial Inc. acquired a new stake in Upstream Bio in the 4th quarter worth approximately $142,000.

Upstream Bio Stock Performance

Shares of Upstream Bio stock opened at $8.98 on Wednesday. The firm’s 50 day simple moving average is $7.90 and its two-hundred day simple moving average is $14.37. Upstream Bio, Inc. has a 12-month low of $5.14 and a 12-month high of $29.46.

Upstream Bio Profile

Upstream Bio, Inc, a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease.